CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 350 of 764 entries

View as:

Remote-by-Default Care in the COVID-19 Pandemic

Phase: N/A Priority: Normal

NCT ID: NCT04435041 Org: User:

Start: 05/13/20 End: 02/28/22 Due: 02/28/23

Human Movement Patterns on the Thailand-Myanmar Border

Phase: N/A Priority: Normal

NCT ID: NCT03087214 Org: User:

Start: 03/14/17 End: 02/17/18 Due: 02/17/19

Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function

Phase: N/A Priority: Normal

NCT ID: NCT00232531 Org: User:

Start: 09/30/04 End: 02/28/09 Due: 02/28/10

Malaria Genetic Surveillance in Cambodia

Phase: N/A Priority: Normal

NCT ID: NCT03384472 Org: User:

Start: 06/01/16 End: 02/01/17 Due: 02/01/18

The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction

Phase: N/A Priority: Normal

NCT ID: NCT05878912 Org: User:

Start: 01/20/23 End: 12/31/26 Due: 12/31/27

Investigating Genetic Risk for Type 1 Diabetes

Phase: N/A Priority: Normal

NCT ID: NCT03503747 Org: User:

Start: 04/25/18 End: 08/31/21 Due: 08/31/22

Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

Phase: N/A Priority: Normal

NCT ID: NCT05252845 Org: User:

Start: 01/04/23 End: 09/18/23 Due: 09/18/24

The Oxford Marfan Trial

Phase: N/A Priority: Normal

NCT ID: NCT01949233 Org: User:

Start: 10/31/13 End: 12/31/17 Due: 12/31/18

RCT of Brief Universal Parenting Program to Prevent Child Behavioural and Emotional Difficulties in Greece

Phase: N/A Priority: Normal

NCT ID: NCT02030730 Org: User:

Start: 03/31/12 End: 04/30/13 Due: 04/30/14

Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma

Phase: N/A Priority: Normal

NCT ID: NCT02546544 Org: User:

Start: 03/31/14 End: 07/15/16 Due: 07/15/17

Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?

Phase: N/A Priority: Normal

NCT ID: NCT02498808 Org: User:

Start: 09/30/15 End: 12/31/18 Due: 12/31/19

ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients

Phase: N/A Priority: Normal

NCT ID: NCT02980367 Org: User:

Start: 12/31/16 End: 03/31/22 Due: 03/31/23

Study of Heart and Renal Protection

Phase: N/A Priority: Normal

NCT ID: NCT00125593 Org: User:

Start: 06/30/03 End: 08/31/10 Due: 08/31/11

Lowering Events in Non-proliferative Retinopathy in Scotland

Phase: N/A Priority: Normal

NCT ID: NCT03439345 Org: User:

Start: 07/23/18 End: 02/16/24 Due: 02/16/25

Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

Phase: N/A Priority: Normal

NCT ID: NCT03111810 Org: User:

Start: 05/25/17 End: 08/01/20 Due: 08/01/21

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

Phase: N/A Priority: Normal

NCT ID: NCT00395720 Org: User:

Start: 11/30/06 End: 07/31/10 Due: 07/31/11

Optimising Antibiotic Treatment for Sick Malnourished Children

Phase: N/A Priority: Normal

NCT ID: NCT02746276 Org: User:

Start: 04/01/16 End: 09/30/17 Due: 09/30/18

The PIP Study - Pre- IVF Immune Profiling Study

Phase: N/A Priority: Normal

NCT ID: NCT03660735 Org: User:

Start: 09/26/18 End: 08/01/21 Due: 08/01/22

OxPALM: Oxford Study on Probiotics and Low Mood

Phase: N/A Priority: Normal

NCT ID: NCT03801655 Org: User:

Start: 08/15/18 End: 08/15/20 Due: 08/15/21

Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)

Phase: N/A Priority: Normal

NCT ID: NCT04015648 Org: User:

Start: 10/21/19 End: 03/10/22 Due: 03/10/23

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

Phase: N/A Priority: Normal

NCT ID: NCT00423566 Org: User:

Start: 09/30/02 End: 07/31/03 Due: 07/31/04

Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)

Phase: N/A Priority: Normal

NCT ID: NCT04041973 Org: User:

Start: 03/11/20 End: 03/17/21 Due: 03/17/22

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Phase: N/A Priority: Normal

NCT ID: NCT03117933 Org: User:

Start: 03/09/17 End: 12/31/23 Due: 12/31/24

A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK

Phase: N/A Priority: Normal

NCT ID: NCT05400746 Org: User:

Start: 11/02/22 End: 10/19/23 Due: 10/19/24

Metabolic Imaging of Neurological Disease

Phase: N/A Priority: Normal

NCT ID: NCT06900244 Org: User:

Start: 07/01/21 End: 06/30/27 Due: 06/30/28

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Remote-by-Default Care in the COVID-19 Pandemic	NCT04435041	University of Oxford	user2@example.com	None	2020-05-13	2022-02-28	2023-02-28	-	-	2025-07-14
Human Movement Patterns on the Thailand-Myanmar Border	NCT03087214	University of Oxford	user2@example.com	None	2017-03-14	2018-02-17	2019-02-17	-	-	2025-07-14
Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function	NCT00232531	University of Oxford	user2@example.com	None	2004-09-30	2009-02-28	2010-02-28	-	-	2025-07-14
Malaria Genetic Surveillance in Cambodia	NCT03384472	University of Oxford	user2@example.com	None	2016-06-01	2017-02-01	2018-02-01	-	-	2025-07-14
The Effect of Obesity and Weight Loss in Heart Failure With Preserved Ejection Fraction	NCT05878912	University of Oxford	user2@example.com	None	2023-01-20	2026-12-31	2027-12-31	-	-	2025-07-14
Investigating Genetic Risk for Type 1 Diabetes	NCT03503747	University of Oxford	user2@example.com	None	2018-04-25	2021-08-31	2022-08-31	-	-	2025-07-14
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults	NCT05252845	University of Oxford	user2@example.com	None	2023-01-04	2023-09-18	2024-09-18	-	-	2025-07-14
The Oxford Marfan Trial	NCT01949233	University of Oxford	user2@example.com	None	2013-10-31	2017-12-31	2018-12-31	-	-	2025-07-14
RCT of Brief Universal Parenting Program to Prevent Child Behavioural and Emotional Difficulties in Greece	NCT02030730	University of Oxford	user2@example.com	None	2012-03-31	2013-04-30	2014-04-30	-	-	2025-07-14
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma	NCT02546544	University of Oxford	user2@example.com	None	2014-03-31	2016-07-15	2017-07-15	-	-	2025-07-14
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?	NCT02498808	University of Oxford	user2@example.com	None	2015-09-30	2018-12-31	2019-12-31	-	-	2025-07-14
ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients	NCT02980367	University of Oxford	user2@example.com	None	2016-12-31	2022-03-31	2023-03-31	-	-	2025-07-14
Study of Heart and Renal Protection	NCT00125593	University of Oxford	user2@example.com	None	2003-06-30	2010-08-31	2011-08-31	-	-	2025-07-14
Lowering Events in Non-proliferative Retinopathy in Scotland	NCT03439345	University of Oxford	user2@example.com	None	2018-07-23	2024-02-16	2025-02-16	-	-	2025-07-14
Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition	NCT03111810	University of Oxford	user2@example.com	None	2017-05-25	2020-08-01	2021-08-01	-	-	2025-07-14
The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV	NCT00395720	University of Oxford	user2@example.com	None	2006-11-30	2010-07-31	2011-07-31	-	-	2025-07-14
Optimising Antibiotic Treatment for Sick Malnourished Children	NCT02746276	University of Oxford	user2@example.com	None	2016-04-01	2017-09-30	2018-09-30	-	-	2025-07-14
The PIP Study - Pre- IVF Immune Profiling Study	NCT03660735	University of Oxford	user2@example.com	None	2018-09-26	2021-08-01	2022-08-01	-	-	2025-07-14
OxPALM: Oxford Study on Probiotics and Low Mood	NCT03801655	University of Oxford	user2@example.com	None	2018-08-15	2020-08-15	2021-08-15	-	-	2025-07-14
Safety and Immunogenicity of a Candidate ZIKV Vaccine (ZIKA001)	NCT04015648	University of Oxford	user2@example.com	None	2019-10-21	2022-03-10	2023-03-10	-	-	2025-07-14
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.	NCT00423566	University of Oxford	user2@example.com	None	2002-09-30	2003-07-31	2004-07-31	-	-	2025-07-14
Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)	NCT04041973	University of Oxford	user2@example.com	None	2020-03-11	2021-03-17	2022-03-17	-	-	2025-07-14
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer	NCT03117933	University of Oxford	user2@example.com	None	2017-03-09	2023-12-31	2024-12-31	-	-	2025-07-14
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK	NCT05400746	University of Oxford	user2@example.com	None	2022-11-02	2023-10-19	2024-10-19	-	-	2025-07-14
Metabolic Imaging of Neurological Disease	NCT06900244	University of Oxford	user2@example.com	None	2021-07-01	2027-06-30	2028-06-30	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance